B1Q Stock Overview
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
NRx Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.37 |
52 Week High | US$6.55 |
52 Week Low | US$2.80 |
Beta | 1.03 |
1 Month Change | -26.78% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -98.25% |
Recent News & Updates
Recent updates
Shareholder Returns
B1Q | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 14.1% | 3.9% | 2.0% |
1Y | n/a | -28.2% | 2.0% |
Return vs Industry: Insufficient data to determine how B1Q performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how B1Q performed against the German Market.
Price Volatility
B1Q volatility | |
---|---|
B1Q Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 6.5% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: B1Q's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine B1Q's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | Steve Willard | www.nrxpharma.com |
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital.
NRx Pharmaceuticals, Inc. Fundamentals Summary
B1Q fundamental statistics | |
---|---|
Market cap | €34.49m |
Earnings (TTM) | -€28.19m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs B1Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
B1Q income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$30.16m |
Earnings | -US$30.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.89 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -78.1% |
How did B1Q perform over the long term?
See historical performance and comparison